View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 20, 2020

The impact of the Covid-19 pandemic on clinical trials

By GlobalData Healthcare

The Covid-19 pandemic has the potential to disrupt new and ongoing clinical trials of various medical products. To help combat these complications, on March 18, the FDA issued guidance for the execution of clinical trials during this viral pandemic.

One of the challenges facing the proper conducting of clinical trials is quarantines. Both trial participants and trial personnel may be quarantined and become unavailable for in-person visits. On a related note, trial participants and personnel may also become infected with the virus. An infection in the participants may affect the outcomes of the study and in some cases, some participants may need to be removed from the trial. Additionally, medical centres utilised by the trials may no longer be easily accessible or safe to use. Finally, there may be difficulties with the supply chain, as well as the availability and access to the products being investigated.

The FDA’s new guidance for industry, investigators, and institutional review boards is aimed at ensuring the safety of trial participants as well as the integrity of clinical trials during the Covid-19 pandemic. The FDA states that it recognises the need for amendment of clinical trial protocols due to this evolving health crisis. Changes will depend on the particulars of each trial including participant population, location, and medical products used. One of the recommendations was the assessment of alternatives to in-person visits for communication and patient evaluation. Alternate methods may include phone or virtual visits. Additionally, locations other than hospitals and medical centres, such as labs, may be used.

Depending on the severity and duration of this pandemic, increasing difficulties may arise for conducting clinical trials. This is especially true for trials that are not directly related to Covid-19 prevention or treatment and trials that require in-person access to participants in hospitals and medical facilities.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU